41 reports

  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Influenza
  • Pathology
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Pharmaceutical Market, Chemical Company of Malaysia, Global, Major Products, 2016
  • Healthcare
  • Mortality
  • Pharmaceutical
  • Asia
  • Malaysia
  • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further...

ANNOUNCED THAT ANTI-INFLUENZA DRUG CANDIDATES UNDER ITS FLUCIDE PROGRAM, WHEN GIVEN ORALLY, LED TO STRONG ANTIVIRAL ANTIBODY RESPONSE.

  • Healthcare
  • Influenza
  • Pathology
  • Pharmaceutical
  • Vaccine
  • Daiichi Sankyo Company Ltd - History

In May, Daiichi Sankyo Company, Limited entered into a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute for its influenza HA vaccine " Kaketsuken" .

  • Healthcare
  • Pharmaceutical
  • Japan
  • Company Financials
  • Daiichi Sankyo Company
  • 9.3 BIBLIOGRAPHY

Clinical implications of antiviral resistance in influenza.

  • Clinical Trial
  • Influenza
  • Pathology
  • Therapy
  • Vaccine
  • LANINAMIVIR - DRUG PROFILE

It enables AMRI to develop and manufacture the influenza antiviral products.

  • Influenza
  • Pathology
  • Pharmaceutical
  • Therapy
  • Vaccine
  • LANINAMIVIR - DRUG PROFILE

It enables AMRI to develop and manufacture the influenza antiviral products.

  • Influenza
  • Pathology
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further...

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Healthcare
  • Influenza
  • Pathology
  • Pharmaceutical
  • Vaccine
  • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further...

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Influenza
  • Therapy
  • Vaccine
  • United States
  • Novavax, Inc.
  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Influenza
  • Pathology
  • Pharmaceutical
  • Vaccine
  • Hemispherx Biopharma, Inc.
  • VALUE US$M
  • DRUG PRODUCT
  • Healthcare
  • Manufacturing
  • Pharmaceutical
  • United States
  • Wildwood Ventures Limited
  • RESPIRATORY SYNCYTIAL VIRUS (RSV) - OPPORTUNITY ANALYSIS AND FORECASTS TO 2024

" [Adamantane] influenza antivirals had resistance develop very quickly on therapy...

  • Epidemiology
  • Therapy
  • Vaccine
  • Ablynx NV
  • Gilead Sciences, Inc.
  • PARTNERSHIP - DEAL REPORTS
  • PARTNERSHIP - DEAL REPORTS

a US-based contract research and manufacturing organization, has signed an agreement with Biota Holdings Limited, to further develop and manufacture Biota' s influenza antiviral CS## (laninamivir), a second-generation, long-acting neuraminidase inhibitor.

  • Pharmaceutical
  • Respiratory Treatment
  • United States
  • Company
  • AMRI
  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Influenza
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Hemispherx Biopharma, Inc.
  • FEATURED NEWS & PRESS RELEASES

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Influenza
  • R&D
  • Research And Development
  • Vaccine
  • NanoViricides, Inc.
  • H1N1 Infection - Product Development Milestones

As things stand, there are only two types of antivirals approved for treating the influenza virus (flu virus), including Tamiflu and Relenza, yet multiple strains of the flu virus are increasingly resistant to antivirals.

  • Influenza
  • Pharmaceutical
  • R&D
  • Research And Development
  • Vaccine
  • PARTNERSHIP - DEAL REPORTS
  • DEAL REPORT: BIOTA SCIENTIFIC RECEIVES BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY...
  • Pharmaceutical
  • United Kingdom
  • United States
  • Company
  • Biota Holdings Limited
  • NAS-911 - DRUG PROFILE

In July 2014, New Amsterdam Sciences (NAS) announced the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS lead compound NAS-## as a co-therapeutic for existing influenza antivirals currently available to flu patients.

  • Biotech
  • Pathology
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • Clinical Trial Profile Snapshots

PANDEMIC INFLUENZA ANTIVIRAL AND VACCINE EFFECTIVENESS (EAVE) - USE OF A UNIQUE COMMUNITY AND LABORATORY NATIONAL LINKED DATASET: AN OBSERVATIONAL LONGITUDINAL COHORT STUDY WITH NESTED-CASE CONTROL STUDY EARLY ESTIMATION OF PANDEMIC INFLUENZA ANTIVIRAL AND VACCINE

  • Clinical Trial
  • Drug Discovery And Development
  • Influenza
  • Pathology
  • Vaccine
  • Clinical Trial Profile Snapshots

Pandemic Influenza Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* Prominent Drugs Pandemic Influenza Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* Pandemic Influenza Therapeutics Clinical Tr

  • Clinical Trial
  • Drug Discovery And Development
  • Influenza
  • Pathology
  • Vaccine
  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Infectious Disease
  • Influenza
  • Pharmaceutical
  • Vaccine
  • Hemispherx Biopharma, Inc.
  • 10.2. DEALS BY PRECLINICAL STAGE

antiviral vaccines Collaborative R& D agreement for AVE ## safety and tolerability Licensing agreement for tkRNAi technology Grant award for Parkinson' s disease research Yes Apr 2012 BioVest, US Army Medical Research Institute of Infectious Diseases Sanofi, Michael J Fox Foundatio

  • Infectious Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Wildwood Ventures Limited
  • H3N2 Infection - Product Development Milestones

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Influenza
  • R&D
  • Research And Development
  • Therapy
  • Vaccine
  • Drug Profiles

VH-## elicits antiviral effects.

  • Influenza
  • Pathology
  • R&D
  • Research And Development
  • Vaccine
  • H1N1 Infection - Product Development Milestones

As things stand, there are only two types of antivirals approved for treating the influenza virus (flu virus), including Tamiflu and Relenza, yet multiple strains of the flu virus are increasingly resistant to antivirals.

  • Influenza
  • Pharmaceutical
  • R&D
  • Research And Development
  • Vaccine
  • LANINAMIVIR - DRUG PROFILE

IT ENABLES AMRI TO DEVELOP AND MANUFACTURE THE INFLUENZA ANTIVIRAL PRODUCTS.

  • Cardiovascular Disease
  • Hospital
  • Monoclonal Antibody
  • Therapy
  • Daiichi Sankyo Company
  • Influenza antivirals
  • Description
  • Antiviral
  • Therapy
  • Forecast
  • Market Size
  • NAS-911 - DRUG PROFILE

New Amsterdam Sciences (NAS) announced the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS lead compound NAS## as a co-therapeutic for existing influenza antivirals currently available to flu patients.

  • Pharmaceutical
  • R&D
  • Research And Development
  • Therapy
  • United States
  • NAS-911 - DRUG PROFILE

In July 2014, New Amsterdam Sciences (NAS) announced the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS lead compound NAS-## as a co-therapeutic for existing influenza antivirals currently available to flu patients.

  • Biotechnology
  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • NAS-911 - DRUG PROFILE

IN JULY 2014, NEW AMSTERDAM SCIENCES (NAS) ANNOUNCED THE COMPLETION OF INITIAL CONFIRMATORY STUDIES IN ANIMAL MODELS DESIGNATING OSELTAMIVIR (TAMIFLU) AND NAS LEAD COMPOUND NAS-## AS A CO-THERAPEUTIC FOR EXISTING INFLUENZA ANTIVIRALS CURRENTLY AVAILABLE TO FLU PATIENTS.

  • Biotechnology
  • Pharmaceutical
  • Therapy
  • United States
  • Aeolus Pharmaceuticals, Inc.